Objective: To describe the changes in serum creatinine (Cr) levels after the initiation of gender-affirming hormone therapy (GAHT) in transgender individuals to better understand the expected changes and interpretation of laboratory values in this population.
Methods: A retrospective chart review of all adult transgender patients initiated on GAHT at Mayo Clinic from January 2011 to October 2019 was completed. Laboratory values were obtained prior to initiating GAHT and at 3, 6, and 12 months after initiating GAHT. Baseline Cr values were compared with Cr values at 3, 6, and 12 months after initiating GAHT in transgender men (TM) on testosterone and transgender women (TW) on estradiol and antiandrogens.
Results: A total of 84 TW (median age of 30 years) and 24 TM (median age of 23 years) were included for analysis. Following a matched pair analysis of TW, Cr values were found to be significantly decreased by -0.03 at 3 months (P = .04), -0.10 at 6 months (P < .01), and -0.07 at 12 months (P < .01) compared with baseline values. Following a matched pair analysis of TM, Cr values were found to be significantly increased, on average, by 0.14 at 3 months (P = .04), 0.21 at 6 months (P = .016), and 0.15 at 12 months (P = .003) compared with baseline values.
Conclusion: In TW and TM, a change in Cr level was seen as early as 3 months toward their affirmed gender after initiating GAHT. Clinicians can use Cr levels established at 6 months as new baseline values, as these changes continue to persist up to 12 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eprac.2021.08.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of detransition in persons seeking gender-affirming hormonal treatments: a systematic review.
J Sex Med
December 2024
Centre Universitaire d'Enseignement par Simulation-CUESim, Virtual Hospital of Lorraine, Faculty of Medicine, Midwifery and Health Professions, Université de Lorraine, 9, Avenue de la Forêt de Haye, Vandoeuvre-lès-Nancy, 54505, France.
Background: Despite recent evidence of the benefits of gender-affirming medical procedures, data in the literature indicate emerging demands of detransition and regrets while suggesting potential sources of bias in different datasets, including a nonconsensual definition of detransition.
Aim: The present systematic review aims to summarize the existing research regarding the prevalence of detransition in transgender persons who requested or started receiving gonadotrophin-releasing hormone analogs (GnRHa) and/or gender-affirming hormonal therapy (GAHT).
Methods: A systematic literature search (CINAHL Plus, Cochrane Library, Google Scholar, MEDLINE, Web of Science, Sage Journals, Science Direct, Scopus) for quantitative studies was conducted up to May 2024.
Five-Year Fracture Rate for Transgender and Gender Diverse Patients on Gender-Affirming Hormone Therapy.
J Am Acad Orthop Surg
December 2024
From the University of Michigan Medical School, Ann Arbor, MI (Jacobson), the Department of Physical Medicine and Rehabilitation (Whitney), Department of Orthopedic Surgery (Mamdouhi and Ahn), Consulting for Statistics, Computing and Analytics Research (Janney), and Department of Family Medicine (Blaszczak), University of Michigan, Ann Arbor, MI, and the Department of Orthopaedics, Emory University and Grady Health, Atlanta, GA (Ahn).
Introduction: Gender-affirming hormone therapy (GAHT) is a cornerstone of gender-affirming care for transgender and gender diverse (TGD) patients, with a direct biological role on bone metabolism. However, a paucity of data describes how GAHT influences fracture rate over time. The study's primary objective was to describe the 5-year all-cause fracture incidence rate (IR) among TGD patients initiating estrogen-based GAHT (E-GAHT) or testosterone-based GAHT (T-GAHT), compared with TGD patients not using GAHT (non-GAHT).
View Article and Find Full Text PDFBody composition and perceived stress levels in transgender individuals after one year of gender affirming hormone therapy.
Front Endocrinol (Lausanne)
December 2024
Regional Reference Center for Gender Incongruence (CRRIG) of the Veneto Region, University Hospital of Padova, Padua, Italy.
Introduction: Higher stress levels are linked to increased body fat and decreased bone density, effects that can be exacerbated by lifestyle choices. This is particularly relevant for transgender and gender diverse (TGD) individuals, who often face additional stress from transphobia and social stigma. However, there is limited research on how stress affects body composition and bone health in TGD individuals, particularly in relation to gender-affirming hormone therapy (GAHT).
View Article and Find Full Text PDFTreatment trajectories among children and adolescents referred to the Norwegian National Center for Gender Incongruence.
Acta Paediatr
December 2024
Division of Paediatric and Adolescent Medicine, Department of Child and Adolescent Mental Health in Hospitals, Oslo University Hospital, Oslo, Norway.
Aim: We aimed to describe treatment trajectories, detransition and mortality rate among children and adolescents referred to the Norwegian National Center for Gender Incongruence (NCGI).
Methods: The cohort included all 1258 persons under 18 years at referral to the NCGI from 2000 to 2020. Trajectories were registered until end of 2023.
In Brief: Transgender, non-binary and gender-diverse patients utilizing feminizing gender-affirming hormone therapy (GAHT) may experience reduced fertility, which is currently addressed through fertility preservation and treatment cessation. Experimental research with animal models may identify mechanisms involved in testicular function impairment, their severity and duration, and may help to inform patients about reproductive health decisions.
Abstract: Feminizing GAHT may include combined estrogen, progesterone and/or antiandrogens (collectively referred to as E-GAHT) aiming to achieve individualized embodiment goals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!